Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Caraffini Veronica |
Präsentationen bei wissenschaftlichen und nicht-wissenschaftlichen Veranstaltungen
Telebar, F; Berg, JL; Perfler, B; Bramreiter, B; Caraffini, V; Prokesch, A; Geissler, K; Penz, T; Schuster, M; Reinisch, A; Wölfler, A; Sill, H; Zebisch, A;
Co-occurrence of mutations modifying RAS and EZH2 inactivation in chronic myelomonocytic leukemia causes amplification of RAS-AKT signaling and increases the sensitivity to AKT inhibitors
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology. memo 15 (Suppl 3), 37–67 (2022). . 2022; 15( ):S65--OeGHO- & AHOP-Frühjahrstagung 2022; April 8-10, 2022; Graz, Austria.
[Oral Communication]
FullText
Caraffini, V; Geiger, O; Rosenberger, A; Hatzl, S; Perfler, B; Berg, JL; Lim, C; Strobl, H; Kashofer, K; Hoefler, G; Geissler, K; Kolch, W; Blyth, K; Athineos, D; Wolfler, A; Sill, H; Zebisch, A
Loss of RKIP expression is a frequent event in chronic myelomonocytic leukemia and functionally involved in the pathogenesis of this malignancy
ONCOL RES TREAT. 2018; 41: 27-27.
[Oral Communication]
Web of Science
Caraffini, V; Geiger, O; Rosenberger, A; Hatzl, S; Perfler, B; Berg, JL; Lim, C; Strobl, H; Kashofer, K; Hoefler, G; Geissler, K; Kolch, W; Blyth, K; Athineos, D; Woelfler, A; Sill, H; Zebisch, A
LOSS OF RAF KINASE INHIBITOR PROTEIN IS INVOLVED IN MYELOMONOCYTIC LINEAGE COMMITMENT AND AGGRAVATES THE DEVELOPMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN A MURINE IN-VIVO MODEL
HAEMATOLOGICA. 2017; 102: 148-149.-22nd Congress of the European-Hematology-Association; JUN 22-25, 2017; Madrid, SPAIN.
[Oral Communication]
Web of Science
Caraffini, V; Geiger, O; Rosenberger, A; Hatzl, S; Perfler, P; Berg, JL; Lim, C; Strobl, H; Kashofer, K; Hoefler, G; Geissler, K; Kolch, W; Blyth, K; Athineos, D; Wölfler, A; Sill, H; Zebisch, A
RAF kinase inhibitor protein is involved in the development of chronic myelomonocytic leukemia
memo - Magazine of European Medical Oncology. 2017; 10(2):21-21.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; APR 6-8, 2017; Bregenz, AUSTRIA.
[Poster]
Caraffini, V; Schauer, S; Kashofer, K; Wolfler, A; Hoefler, G; Sill, H; Zebisch, A
RAF KINASE INHIBITOR PROTEIN IS INVOLVED IN THE DEVELOPMENT OF MYELOID SARCOMA
HAEMATOLOGICA. 2017; 102: 361-362.-22nd Congress of the European-Hematology-Association; JUN 22-25, 2017; Madrid, SPAIN.
[Poster]
Web of Science
Caraffini, V; Schauer, S; Kashofer, K; Wölfler, A; Hoefler, G; Sill, H; Zebisch A
Loss of RAF kinase inhibitor Protein in myeloid sarcoma
memo - Magazine of European Medical Oncology
. 2017; 10(2):31-31.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology
; APR 6-8, 2017; Bregenz, AUSTRIA.
[Poster]
Kashofer, K; Gornicec, M; Caraffini, V; Lind, K; Schauer, S; Beham-Schmid, C; Wölfler, A; Hoefler, G; Sill, H; Zebisch, A
Genetic aberrations of myeloid sarcomas
memo - Magazine of European Medical Oncology
. 2017; 10(2):28-28.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology
; APR 6-8, 2017; Bregenz, AUSTRIA.
[Poster]